Syngoi Technologies Expands DNA Manufacturing Capacity After Series B Investment.
- Syngoi’s funding round enables production of DNA at kilograms scale and accommodates over 15 concurrent projects.
- Asahi Kasei Medical, subscribe to the funding, together with Columbus VP.
- Damiá Tormo, Syngoi’s Chairman, anticipates “double-digit growth” driven by high demand for DNA in advanced therapies.
June 10, 2024. Zamudio. Syngoi Technologies SLU, a leading Contract Development and Manufacturing Organization (CDMO) specializing in synthetic DNA for advanced cell and gene therapies, announces a significant expansion in its production capabilities, enabling the production of DNA at kilograms scale and accommodating more than 25 concurrent customer projects. This expansion follows a successful Series B capital raise – led by Columbus Venture Partners and subscribed to by Asahi Kasei Medical – validating Syngoi’s pivotal role in this emerging segment of the pharmaceutical industry.
Synthetic optimized DNA serves as a critical component in various therapeutic applications such as mRNA and DNA vaccines, CART-cell therapy, gene editing, viral gene therapy, and non-viral gene therapy. Syngoi’s innovative approach enables the customization of synthetic DNA to enhance therapeutic efficacy while reducing costs per dose.
Located in the technological hub of Zamudio (Bizkaia) in the Basque Country, Syngoi is at the forefront of developing and manufacturing tailored synthetic DNA to optimize therapeutic outcomes. The company’s state-of-the-art facilities utilize a unique platform that streamlines production, significantly reducing delivery times and enhancing purity compared to traditional methods.
“We are forecasting double digit growth due to the high demand for advanced therapies where DNA is the critical component. In the next years the market of advanced therapies will grow intensively”, said Damiá Tormo, Chairman of Syngoi Technologies and Founding Partner at Columbus Venture Partners. “Also, we are thrilled to announce the expansion of our manufacturing capacity, made possible by the support of Asahi Kasei “, Tormo added.
Tomoyuki Miyabayashi, Senior General Manager of Research and Business Development at Asahi Kasei Medical, commented, “Syngoi’s innovative approach and agility in delivering results make it a strategic investment in the realm of cell and gene therapy. We are excited to partner with Syngoi as it continues to drive advancements in this transformative field”.
Julen Oyarzabal, CSO at Syngoi and Partner at Columbus VP, added, “Our technology empowers us to tailor synthetic DNA to specific therapeutic needs, offering unparalleled opportunities for treatment optimization. With this capital infusion, we are poised to further accelerate innovation and meet the evolving demands of our customers”.
“Since its inception, Syngoi’s funnel of projects has been increasing rapidly. Our customer base has grown quickly. Customers have already evaluated our approach and have selected our synthetic DNA for the development of their therapies,” commented José Vicente Pons, Head of Business Development at Syngoi Technologies. “With this financing round, we can gain access to high-demanding customers that need rapid reaction times and fast delivery with higher DNA quality”, Pons added.
The Series B capital increase will empower Syngoi to ramp up its Good Manufacturing Practice (GMP) manufacturing capacity. This expansion will not only address current demands but also position Syngoi to capitalize on the anticipated growth in the advanced therapies market.
About Syngoi Technologies
Syngoi Technologies is a CDMO specialized in the manufacturing of synthetic DNA used in advanced cell and gene therapies. The company was founded in 2021 by Columbus Venture Partners and it’s located at the technology park of Zamudio (Bizkaia, Spain).
For more information about Syngoi Technologies, visit www.syngoi.com
About Columbus Venture Partners
Columbus Venture Partners is a Spanish venture capital firm that brings a unique approach for investing in outstanding opportunities in all stages of biopharmaceutical drug development and advanced manufacturing technologies for biopharmaceuticals. Columbus VP manages over $250 million allocated in its three funds and have built an impressive performance track record with recently successful exits on Viralgen, AskBio, PTS, Sanifit or Recovid among others. Columbus’ professional team combines a solid scientific, medical, and business corporate knowledge with a wide experience in business biotech field.
About Asahi Kasei Medical
Asahi Kasei Medical is a core operating company in the Asahi Kasei Group’s Health Care sector. Its medical device business offers blood purification filters and systems, and its bioprocess business comprises filters, biosafety testing services, and biologics CDMO operations, enabling safe and efficient biotherapeutics production.
For more information, visit www.asahi-kasei.co.jp/medical/en
